Gill Capital Partners’s AbbVie ABBV Stock Holding History

Gill Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$346K	Sell	1,590 -23	-1%	-$5.1K	0.1%	96
2025 Q4	$369K	Hold	1,613	–	–	0.11%	90
2025 Q3	$373K	Sell	1,613 -730	-31%	-$149K	0.11%	90
2025 Q2	$435K	Buy	2,343 +1	+0%	+$186	0.14%	83
2025 Q1	$491K	Buy	2,342 +601	+35%	+$117K	0.17%	75
2024 Q4	$309K	Buy	1,741 +701	+67%	+$129K	0.11%	91
2024 Q3	$205K	Buy	+1,040	New	+$194K	0.07%	122

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gill Capital Partners's ABBV Position: Q1 2026 in Review

Gill Capital Partners reduced its AbbVie (ABBV) stake by 1.4% in Q1 2026, selling an estimated $5.1K and leaving 1,590 shares worth $346K. The position accounts for 0.1% of the portfolio, ranked #96.

Gill Capital Partners first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. The position peaked at $491K in Q1 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Gill Capital Partners held 1,590 shares of AbbVie worth $346K as of Q1 2026.
Gill Capital Partners sold 23 AbbVie shares in Q1 2026, an estimated $5.1K.
AbbVie made up 0.1% of Gill Capital Partners's portfolio in Q1 2026, its #96 holding.
Gill Capital Partners first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
Gill Capital Partners's AbbVie position peaked at $491K in Q1 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.